Table 2

HRs for discontinuing treatment with (A) biosimilar versus originator (reference) infliximab, (B) biosimilar versus originator (reference) etanercept

CT-P13 versus INF
HR (95% CI)
SB4 versus ETN
HR (95% CI)
Crude0.95 (0.79 to 1.15)0.82 (0.63 to 1.07)
 Sex, age, csDMARD0.94 (0.78 to 1.14)0.84 (0.64 to 1.09)
 Sex, age, csDMARD, CRP0.94 (0.78 to 1.14)0.84 (0.65 to 1.09)
 Sex, age, csDMARD, patient global0.93 (0.77 to 1.13)0.84 (0.65 to 1.09)
  • *Adjusted for baseline characteristics, all patients are included in the multivariable analyses due to the categorisation of the variables (see Patients and methods section).

  • CRP, C reactive protein;csDMARD, conventional synthetic disease-modifying antirheumatic drug; CT-P13, infliximab biosimilar; ETN, etanercept originator; INF, infliximab originator; SB4, etanercept biosimilar.